Albiges L - Search Results

1

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK. de Velasco G, et al. Among authors: albiges l. Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197. Epub 2015 Nov 20. Cancer Immunol Res. 2016. PMID: 26589768

2

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.

Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ. Lassau N, et al. Among authors: albiges l. Clin Cancer Res. 2010 Feb 15;16(4):1216-25. doi: 10.1158/1078-0432.CCR-09-2175. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145174

3

How to select targeted therapy in renal cell cancer.

Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. Escudier B, et al. Among authors: albiges l. Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371. Ann Oncol. 2010. PMID: 20943644 Free article. Review.

4

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.

Escudier B, Albiges L. Escudier B, et al. Among authors: albiges l. Drugs. 2011 Jun 18;71(9):1179-91. doi: 10.2165/11591410-000000000-00000. Drugs. 2011. PMID: 21711062 Review.

5

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.

Albiges L, Salem M, Rini B, Escudier B. Albiges L, et al. Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006. Hematol Oncol Clin North Am. 2011. PMID: 21763969 Review.

6

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.

Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, Rini BI. Sadeghi S, et al. Among authors: albiges l. Cancer. 2012 Jul 1;118(13):3277-82. doi: 10.1002/cncr.26666. Epub 2011 Dec 2. Cancer. 2012. PMID: 22139966 Free article.

7

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Albiges L, et al. J Clin Oncol. 2012 Feb 10;30(5):482-7. doi: 10.1200/JCO.2011.37.2516. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231040

8

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P. Albiges L, et al. Ann Oncol. 2012 Aug;23(8):1943-1953. doi: 10.1093/annonc/mds115. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689175 Free article. Review.

9

Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

Albiges L, Molinie V, Escudier B. Albiges L, et al. Oncologist. 2012;17(8):1051-62. doi: 10.1634/theoncologist.2012-0038. Epub 2012 Jul 17. Oncologist. 2012. PMID: 22807514 Free PMC article. Review.

10

False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.

Wagner M, Bellmunt J, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K. Wagner M, et al. Among authors: albiges l. Clin Genitourin Cancer. 2013 Mar;11(1):66-9. doi: 10.1016/j.clgc.2012.06.006. Epub 2012 Sep 13. Clin Genitourin Cancer. 2013. PMID: 22981209 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

328 results

Search Page

Filters